ArticleMolecular neurobiology2026
Fructooligosaccharides Restore Gut Function and Increase Hippocampal Short-Chain Fatty Acids to Alleviate Neuronal Apoptosis Induced by Mitochondrial Autophagy in rats with Chronic Cerebral Hypoperfusion.
Article in Molecular neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Chronic cerebral hypoperfusion (CCH) contributes to vascular dementia (VaD) through intestinal dysfunction, reduced hippocampal short-chain fatty acids (SCFAs), neuroinflammation, mitochondrial dysfunction, and neuronal apoptosis. This study investigated whether fructooligosaccharides (FOS) alleviate CCH-induced cognitive and intestinal dysfunction and explored the potential involvement of SCFA-associated gut-brain signaling. CCH was induced in male Sprague-Dawley rats by bilateral common carotid artery occlusion (BCCAO). Rats were assigned to Sham, BCCAO, Sham + FOS, and BCCAO + FOS groups, and FOS were administered orally at 14 g/kg/day for four weeks. Cognitive function, intestinal barrier integrity, hippocampal SCFAs, neuroinflammation, apoptosis, and mitophagy were assessed. Primary neurons exposed to hypoxia were treated with SCFAs to evaluate apoptosis and mitophagy. FOS improved locomotor activity, anxiety-like behavior, spatial learning, and memory in BCCAO rats. FOS restored colonic goblet cells (P < 0.001) and ZO-1 expression (P < 0.01) and reduced intestinal TNF-α, IL-6, IL-17, and IL-33 levels (P < 0.05). In the hippocampus, FOS increased acetate and valerate levels (P < 0.05), decreased TNF-α and IL-33 expression, reduced cleaved caspase-3 (P < 0.01), preserved NeuN-positive neurons (P < 0.05), and alleviated mitochondrial injury. BCCAO-induced increases in P62, LC3B, Beclin-1, BNIP3, and NIX (P < 0.05) were attenuated by FOS, whereas PINK1/Parkin signaling remained unchanged. In primary neurons, SCFAs reduced CoCl₂-induced apoptosis and BNIP3/NIX activation and preserved MAP2/Tau-positive neuronal morphology. FOS alleviated intestinal barrier dysfunction, neuroinflammation, neuronal apoptosis, and cognitive impairment after CCH. These effects were accompanied by increased hippocampal SCFAs and changes in BNIP3/NIX-related mitophagy, supporting a potential role for SCFA-associated gut-brain signaling in FOS-mediated neuroprotection.
Indexed as
Identifiers
42726175What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.